Zhitong Finance APP learned that UBS issued a research report stating that it gave WuXi Biologics (02269) a "buy" rating with a target price of HK $142, and raised its 2021-23 earnings per share forecast by 26% to 38% to reflect the epidemic and CMO-related projects were stronger than expected, and the 2020-24 revenue forecast was raised by 11% to reflect the stronger-than-expected growth of new crown projects and the growth of drug production outsourcing (CMO). According to the report, according to the management, there will be at least four to five non-Novel Coronavirus-related CMOs before the end of 2022, which is estimated to drive the company's long-term profit growth. The management will maintain the 2021...
- 1
- 1
- Favorite
UBS: Give WuXi Biologics (02269) a "buy" rating with a target price of HK $142
智通财经2021-08-30
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
1
Report
Login to post
- 记事本2020·2021-08-306661Report
Most Discussed
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email：uservice@ttm.financial